DiaMonTech AG – The Future of Non-Invasive Blood Glucose Monitoring

DiaMonTech AG is an innovative MedTech company developing a globally unique technology for non-invasive blood glucose measurement. Its goal is to enable millions of people living with diabetes to monitor their blood sugar levels pain-free, continuously, and accurately – without finger pricking and without disposable consumables. DiaMonTech’s patented technology is based on infrared spectroscopic glucose measurement and is primarily aimed at B2B partners in the medical technology, diagnostics, and medical device industries. In doing so, the company addresses a global multi-billion-euro market with significant growth potential.

Strong Investors and Co-Investments at Eye Level

The digital business angel network Companisto has been supporting DiaMonTech AG in an advanced growth stage. To date, approximately EUR 8 million have been invested by Companisto investors. At the same time, the international technology group Samsung participated in the company with a EUR 1.5 million co-investment. Other renowned investors include a world-leading medical technology company, the US venture capital fund Unorthodox Ventures, and the European Institute of Innovation & Technology (EIT). This high-profile investor base highlights the technological relevance and commercial potential of DiaMonTech AG and confirms the quality of the selection made by Companisto.

Companisto as a Growth Partner

DiaMonTech AG’s success story exemplifies that Companisto not only finances startups in their early stages, but also provides targeted support to young stock corporations during their growth and scaling phases. Together with professional co-investors, Companisto enables private investors to gain access to attractive investment opportunities in the MedTech sector. The funds raised through Companisto are being used, among other things, to further develop and industrialize the measurement devices, conduct clinical studies and regulatory approval processes, expand strategic B2B partnerships, and prepare for the international market launch.

High Demand and Limited Share Packages

DiaMonTech AG’s funding round was characterized by exceptionally high demand and was therefore successfully closed ahead of schedule. Due to the continued strong interest, Companisto was able to secure an additional – though highly limited – share package for its investor community in close coordination with the company.